AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

(Reuters) -AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday. Patients showed a... NORTH CHICAGO ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

Abbvie Regional Account Executive. Hunter has over 25 years of experience in the neuroscience field focusing on patients with acute ischemic stroke, multiple sclerosis and Parkinson's disease. Over ...

A nurse prepares to administer a malaria vaccine to an infant at the health center in Datcheka, Cameroon January 22, 2024. REUTERS/Desire Danga Essigue/File Photo The U.S. government's foreign aid ...